Aegerion To Pay $40M To End Host Of Juxtapid Claims
Massachusetts-based biopharmaceutical company Aegerion Pharmaceuticals Inc. agreed Friday to pay about $40 million to end criminal and civil allegations by the U.S. Department of Justice and fraud charges brought by the...To view the full article, register now.
Already a subscriber? Click here to view full article